SCHEMBL61597

SCHEMBL61597

NC(=O)c1c2ccccc2nc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.52
KDM4E B2RXH2 3/20 0.52
GLA P06280 3/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HPGD P15428 2/20 0.52
CASP1 P29466 2/20 0.52
CASP7 P55210 2/20 0.52
MAOA P21397 2/20 0.52
CHRM2 P08172 1/20 0.52
ADRA2A P08913 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
CHRM1 P11229 1/20 0.52
NQO2 P16083 1/20 0.52
DRD1 P21728 1/20 0.52
ACHE P22303 1/20 0.52
SLC6A2 P23975 1/20 0.52
ADRA1A P35348 1/20 0.52
OPRM1 P35372 1/20 0.52
KCNH2 Q12809 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30148539 1.00 HSD17B10 (0.52) HSD17B10KDM4EGLAALDH1A1SMN1; SMN2
SCHEMBL1420724 0.94 NCOA1 (0.47) HSD17B10KDM4EGLAALDH1A1SMN1; SMN2
SCHEMBL27550242 0.82 PDE10A (0.55) HSD17B10KDM4EGLAALDH1A1SMN1; SMN2
SCHEMBL641899 0.82 PDE10A (0.66) HSD17B10KDM4EGLAALDH1A1SMN1; SMN2
SCHEMBL29377848 0.82 PDE10A (0.66) HSD17B10KDM4EGLAALDH1A1SMN1; SMN2
SCHEMBL29864783 0.81 PDE10A (0.75) HSD17B10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL20659212 0.81 PDE10A (0.75) HSD17B10KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL8168011 0.81 PDE10A (0.47) HSD17B10ALDH1A1HPGDPDE10ATP53
SCHEMBL3402941 0.81 AKR1B1 (0.47) HSD17B10KDM4EGLAALDH1A1HPGD
Hydrochloric Acid SCHEMBL1603404 0.80 PDE10A (0.63) HSD17B10KDM4EGLAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111886315-B Sealing material for display element, cured product thereof, frame sealing material for organic EL element, and face sealing material for organic EL element 三井化学株式会社 2023-06-30 CN claimed
CN-111886315-A Sealing material for display element, cured product thereof, frame sealing material for organic EL element, and surface sealing material for organic EL element 三井化学株式会社 2020-11-03 CN claimed
US-10641768-B2 Methods and kits for decreasing interferences from leukocytes in specific binding assays ABBOTT JAPAN CO. LTD. (JP) 2020-05-05 US claimed
WO-2019181592-A1 ENCAPSULATING MATERIAL FOR DISPLAY ELEMENT AND CURED PRODUCT THEREOF, FRAME ENCAPSULATING MATERIAL FOR ORGANIC EL ELEMENT, AND SURFACE ENCAPSULATING MATERIAL FOR ORGANIC EL ELEMENT 三井化学株式会社 2019-09-26 WO claimed
CN-103764140-B Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases 韩国化学研究院 2017-05-17 CN claimed
CN-103764140-A Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases KOREA RES INST CHEM TECH 2014-04-30 CN claimed
US-20140072996-A1 METHODS AND KITS FOR DETECTING HEMOGLOBIN IN TEST SAMPLES ABBOTT LABORATORIES (US) 2014-03-13 US claimed
US-8574858-B2 Autoantibody enhanced immunoassays and kits ABBOTT LABORATORIES (US) 2013-11-05 US claimed
EP-2598534-A1 ANTIBODIES RELATING TO PIVKA-II AND USES THEREOF Abbott Laboratories (US) 2013-06-05 EP claimed
US-20130029353-A1 AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS ABBOTT LABORATORIES (US) 2013-01-31 US claimed
WO-2008051762-A2 IMMUNOASSAY OF ANALYTES IN SAMPLES CONTAINING ENDOGENOUS ANTI-ANALYTE ANTIBODIES ABBOTT LABORATORIES (US) 2008-05-02 WO claimed
WO-2008051761-A2 ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES ABBOTT LABORATORIES (US) 2008-05-02 WO claimed
US-20080102481-A1 Assay for cardiac troponin autoantibodies ABBOTT LABORATORIES 2008-05-01 US claimed
US-7329493-B2 One-tube nested PCR for detecting Mycobacterium tuberculosis ASIAGEN CORPORATION (TW) 2008-02-12 US claimed
US-20060210966-A1 Kits and methods for detecting bovine ephemeral fever virus ASIAGEN CORPORATION 2006-09-21 US claimed
US-20060134648-A1 One-tube nested PCR for detecting mycobacterium tuberculosis ASIAGEN CORPORATION 2006-06-22 US claimed
US-20050244835-A1 Methods, kits and assay system for detecting drug-resistant Mycobacterium tuberculosis ASIAGEN CORPORATION 2005-11-03 US claimed
US-20050123933-A1 Assay systems, kits and methods for detecting microorganisms ASIAGEN CORPORATION 2005-06-09 US claimed
US-20040219564-A1 DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds ASIAGEN CORPORATION (TW) 2004-11-04 US claimed
US-20040219538-A1 DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds ASIAGEN CORPORATION 2004-11-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219538-A1 DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds DNMT1, ACR, DNMT3A HSD17B10 1931/4885KDM4E 957/4885GLA 866/4885
US-20060134648-A1 One-tube nested PCR for detecting mycobacterium tuberculosis TERT, POLRMT, MRM1 HSD17B10 2020/4885KDM4E 3236/4885GLA 2167/4885
US-20040219564-A1 DNA labeling reagents, acridinium-9-carboxamide derivatives and process of preparing DNA labeling compounds DNMT1, ACR, DNMT3A HSD17B10 1931/4885KDM4E 957/4885GLA 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.